Sirolimus for calcineurin inhibitors in organ transplantation: contra

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Sirolimus (SRL), an mTOR inhibitor, was investigated as a non-nephrotoxic alternative to calcineurin inhibitors for renal transplant rejection.
• Initial enthusiasm for SRL waned due to clinical trials revealing increased rejection rates and no superior graft function compared to existing treatments.

Purpose of the Study:

• To evaluate the efficacy and safety of Sirolimus (SRL) in preventing acute rejection in renal transplantation.
• To explore the immunological mechanisms underlying SRL's effects on alloimmune responses.
• To assess the overall tolerability and adverse event profile of SRL therapy in transplant patients.

Main Methods:

• Review of clinical trial data and immunological studies on Sirolimus (SRL) in renal transplantation.
• Analysis of SRL's impact on T cell subsets and innate immune responses.
• Assessment of SRL's safety profile, including adverse events and graft function.

Main Results:

• Sirolimus (SRL) demonstrated an increased risk of acute rejection and did not outperform cyclosporine or tacrolimus in graft function.
• SRL exhibits immunosuppressive effects on CD4+ T cells but paradoxically stimulates innate immunity, contributing to incomplete alloimmune control.
• SRL therapy is associated with significant adverse effects, including delayed graft function, proteinuria, dyslipidemia, diabetes, and interstitial pneumonia.

Conclusions:

• Sirolimus (SRL) is not an ideal antirejection drug due to incomplete immune response control and poor tolerability.
• Despite limitations in transplantation, emerging evidence of mTOR pathway involvement in other diseases suggests potential new applications for SRL.